ISRN Medicinal Chemistry

Volume 2013 (2013), Article ID 492604, 8 pages

http://dx.doi.org/10.1155/2013/492604

Research Article

Regioselective Synthesis of Dispiro Pyrrolizidines as Potent Antimicrobial Agents for Human Pathogens

N. Sirisha and R. Raghunathan

Department of Organic Chemistry, University of Madras, Guindy Campus, Chennai 600 025, India

Received 24 June 2013; Accepted 18 July 2013

Academic Editors: C.-Y. Gong and L. Soulère

Copyright © 2013 N. Sirisha and R. Raghunathan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Synthesis of a series of novel dispiro pyrrolizidines has been accomplished by 1,3-dipolar cycloaddition reaction of azomethine ylide generated from secondary amino acids and diketones with bischalcones. These compounds were evaluated for their antibacterial activity. Most of the synthetic compounds exhibited good antibacterial activity against microorganisms.

1. Introduction

1,3-dipolar cycloaddition is one of the important tools for the construction of five membered heterocycles [1], and many important natural products have been synthesized by this method [2, 3]. Pyrrolidine-based natural products are very useful in preventing and treating rheumatoid arthritis, asthma, and allergies and also possess anti-influenza virus and anticonvulsant activities [4]. The azomethine ylide represents one of the most reactive and versatile classes of 1,3-dipoles and is readily trapped by a range of dipolarophiles forming substituted pyrrolidines [5]. Spiro compounds represent an important class of naturally occurring substances characterized by highly pronounced biological properties [6, 7].

Chalcones belong to the broad class of compounds present in almost all vascular plants, not only in their terrestrial parts but also in roots, as well as in flakes and seeds. Chalcones are precursors of flavonoids and play a crucial role in their biosynthesis [8, 9]. Depending on the substitution pattern on the two aromatic rings, a wide range of pharmacological activities has been identified for various chalcones [10, 11]. These include among others cytotoxic, antiprotozoal [12], antibacterial, antifungal [13], and antitumor activities [14, 15]. More recently, there has been strong interest in the antimalarial activity of chalcones and bischalcones [16].

As a part of the ongoing research program on the synthesis of complex novel spiro heterocycles [17], herein we report for the first time an expeditious protocol for the synthesis of novel dispiro pyrrolizidines through 1,3-dipolar cycloaddition reaction of azomethine ylide generated from various diketones and secondary amino acids with bischalcones derived from terephthalaldehyde and substituted acetophenones as dipolarophiles. The synthesized compounds were screened for antimicrobial activity, and the results are presented in this paper.

2. Materials and Methods

2.1. General Procedure for the Synthesis of Bischalcones 3a–c

A solution of substituted acetophenone (2 equiv) and terephthalaldehyde (1 equiv) in methanolic solution of NaOH (60%) was stirred for 20 h at room temperature. The solution was poured into ice-cold water at pH 2 (pH adjusted by HCl). The solid separated was dissolved in CH₂Cl₂, washed with saturated solution of NaHCO₃, and evaporated to dryness. The residue was purified by column chromatography using hexane, ethyl acetate mixture (9 : 1) as eluent. The compound was recrystallized in chloroform.

(2E,2′E)-3,3′-(1,4-Phenylene)bis(1-phenylprop-2-en-1-one) ( 3a ). Pale yellow solid, yield 81%; m.p. 158°C; IR, 1653, 1610, 1541. ¹H NMR (CDCl₃, 300 MHz): δ 2.18 (s, 6H), 6.83 (d, J = 16 Hz, 2H), 7.24–7.51 (m, 8H), 7.75 (d, 4H), 8.02 (d, J = 16 Hz, 2H); ¹³C NMR (75 MHz); ppm 122.51, 128.08, 129.32, 131.14, 136.78, 138.45, 142.82, 192.37. MS (EI); m/z = 339.1. Anal. Calc. for C₂₄H₁₈O₂: C, 85.17; H. 5.3; found: C. 85.5; H 5.73.

(2E,2′E)-3,3′-(1,4-Phenylene)bis(1-p-tolylprop-2-en-1-one) ( 3b ). Pale yellow solid, yield 75%; m.p. 178°C; IR, 1653, 1610, 1541. ¹H NMR (CDCl₃, 300 MHz): δ 6.9 (d, J = 15 Hz, 2H), 7.25–7.49 (m, 10H), 7.6 (d, 4H), 7.92 (d, J = 15 Hz, 2H); ¹³C NMR (75 MHz); ppm 31.22, 123.02, 128.51, 128.68, 132.94, 136.86, 138.05, 143.53, 194.4. MS (EI); m/z = 367.4. C₂₆H₂₂O₂: C, 85.22; H, 6.05; found: C. 85.41; H 5.94.

(2E,2′E)-3,3′-(1,4-phenylene)bis(1-(2-hydroxyphenyl)prop-2-en-1-one) ( 3c ). Pale yellow solid, yield 83%; m.p. 190°C; IR, 1653, 1610, 1541. ¹H NMR (CDCl₃, 300 MHz): δ 6.72 (d, J = 14 Hz, 2H), 7.15–7.32 (m, 8H), 7.5 (d, 4H), 7.89 (d, J = 14 Hz, 2H), 11.68 (s, 2H); ¹³C NMR (75 MHz); ppm 124.21, 127.34, 128.61, 129.52, 133–91, 138.11, 139.17, 144.92, 196.35. MS (EI); m/z = 371.4. Anal. Calc. for C₂₄H₁₈O₄: C, 77.82; H, 4.90; found: C. 77.95; H 5.01.

2.2. General Procedure for Synthesis of Cycloadducts, 6a–c and 8a–c

To a solution of acenaphthenequinone 5/isatin 7 (2 eq), proline 4 (3 eq) in dry toluene (15 mL) bischalcones 3a–c (1eq) was added. The solution was refluxed until the completion of the reaction (5–7 h) as evidenced by TLC analysis. The solvent was removed in vacuo, and the crude product was subjected to column chromatography on silica gel (100–200 mesh) using petroleum ether/ethyl acetate (8 : 2) as eluent.

(1R,1′R,2′R,7a′S)-2′-Benzoyl-1′-(4-((1S,1′S,2′S,7a′R)-2′-benzoyl-2-oxo-1′,2′,5′,6′,7′,7a′-hexahydro-2H-spiro[acenaphthylene-1,3′-pyrrolizine]-1′-yl)phenyl)-1′,2′,5′,6′7′,7a′-hexahydro-2H-spiro[acenaphthylene-1,3′-pyrrolizin]-2-one ( 6a ). Yellow solid, yield: 66%. m.p: 172°C. IR (KBr): 1724, 1649 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz): δ 1.73–1.92 (m, 4H), 1.96 (m, 2H), 2.38 (m, 2H), 2.63 (m, 2H), 3.93 (m, 2H), 4.24 (m, 2H), 4.94 (d, 2H J = 11.4 Hz), 5.25 (m, 2H), 6.73–7.83 (m, 26H). ¹³C NMR (75 MHz); ppm 26.87, 30.39, 48.80, 53.09, 64.52, 72.13, 77.13. 121.73, 124.32, 125.12, 127.28, 127.39, 127.71, 127.87, 128.16, 128.52, 128.67, 130.30, 131.49, 132.19, 134.88, 137.07, 138.62, 141.75, 198.33, 206.41. MS (EI); m/z = 809.5 (M⁺). Anal. Calcd for: C₅₆H₄₄N₂O₄: C, 83.14; H, 5.48; N, 3.46; found; C, 83.23; H, 5.43; N, 3.50.

(1R,1′R,2′R,7a′S)-2′-(4-Methylbenzoyl)-1′-(4-((1S,1′S,2′S,7a′R)-2′-(4-methylbenzoyl)-2-oxo-1′,2′,5′,6′,7′,7a′-hexahydro-2H-spiro[acenaphthylene-1,3′-pyrrolizine]-1′-yl)phenyl)-1′,2′,5′,6′,7′,7a′-hexahydro-2H-spiro[acenaphthylene-1,3′-pyrrolizin]-2-one ( 6b ). Yellow solid, yield: 69%. m.p: 158°C. IR (KBr): 1737, 1657 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz): δ 1.72–1.79 (m, 4H), 1.82–1.88 (m, 2H), 1.96 (s, 6H), 2.38 (m, 2H), 2.65 (m, 2H), 3.94 (m, 2H), 4.19–4.26 (m, 2H), 4.91 (d, 2H J = 11.10 Hz), 5.22 (m, 2H), 6.56–7.84 (m, 24H). ¹³C NMR (75 MHz); ppm 20.20, 25.77, 29.27, 47.80, 52.19, 63.18, 71.02, 76.44, 120.68, 123.35, 124.02, 126.56, 126.85, 127.41, 127.45, 129.32, 130.43, 130.51, 133.63, 133.95, 137.60, 140.79, 141.90, 196.86, 205.33. MS (EI); m/z = 837.3 (M⁺). Anal. Calcd for: C₅₈H₄₈N₂O₄: C, 83.23; H, 5.78; N, 3.35; found; C, 83.34; H, 5.69; N, 3.29.

(1R,1′R,2′R,7a′S)-2′-(2-Hydroxybenzoyl)-1′-(4-((1S,1′S,2′S,7a′R)-2′-(2-hydroxybenzoyl)-2-oxo-1′,2′,5′,6′,7′,7a′-hexahydro-2H-spiro[acenaphthylene-1,3′-pyrrolizine]-1′-yl)phenyl)-1′,2′,5′,6′,7′,7a′-hexahydro-2H-spiro[acenaphthylene-1,3′-pyrrolizin]-2-one ( 6c ). Yellow solid, yield: 71%. m.p: 134°C. IR (KBr): 3038, 1727, 1642  cm⁻¹; ¹H NMR (CDCl₃, 300 MHz): δ 1.73–1.91 (m, 4H), 1.94–2.01 (m, 2H), 2.27 (m, 2H), 2.54 (m, 2H), 3.79 (m, 2H), 4.08 (m, 2H), 4.82 (d, J = 11.4 Hz, 2H), 5.19 (m, 2H), 6.59–7.83 (m, 24H). 12.17 (s, 2H). ¹³C NMR (75 MHz); ppm 26.09, 29.38, 48.10, 53.37, 63.98, 71.69, 76.22, 119.92, 120.34, 121.79, 121.98, 122.37, 123.78, 125.47, 126.76, 128.98, 129.15, 131.18, 132.75, 136.20, 140.81, 141.82, 197.18, 205.43 MS (EI); m/z = 841.2 (M⁺). Anal. Calcd for: C₅₆H₄₄N₂O₆: C, 79.98; H, 5.27; N, 3.33; O, 11.42; found; C, 80.09; H, 5.31; N, 3.24.

(2′R,3R)-2′-Benzoyl-1′-(4-((2′S,3S)-2′-benzoyl-2-oxo-1′,2′,5′,6′,7′,7a′-hexahydrospiro[indoline-3,3′-pyrrolizine]-1′-yl)phenyl)-1′,2′,5′,6′,7′,7a′-hexahydrospiro[indoline-3,3′-pyrrolizin]-2-one ( 8a ). Yellow solid, yield: 61%. m.p: 152°C. IR (KBr): 1712, 1644 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz): δ 1.49–1.57 (m, 4H), 1.70–1.77 (m, 2H), 1.89 (m, 2H), 2.01 (m, 2H), 2.19 (m, 2H), 2.54 (m, 2H), 3.55 (d, J = 11.10 Hz, 2H), 4.18 (m, 2H), 6.41–7.66 (m, 22H), 8.10 (s, 2H). ¹³C NMR (75 MHz); ppm 25.12, 26.39, 31.41, 42.03, 52.75, 62.19, 71.17, 120.93, 122.76, 125.53, 126.92, 127.52, 128.81, 129.08, 129.93, 131.61, 136.90, 140.08, 141.17, 181.33, 199.81. MS (EI); m/z = 739.2 (M⁺). Anal. Calcd for: C₄₈H₄₂N₂O₄: C, 78.03; H, 5.73; N, 7.58; found; C, 78.12; H, 5.81; N, 7.42.

(2′R,3R)-2′-(4-Methylbenzoyl)-1′-(4-((2′S,3S)-2′-(4-methylbenzoyl)-2-oxo-1′,2′,5′,6′,7′,7a′-hexahydrospiro[indoline-3,3′-pyrrolizine]-1′-yl)phenyl)-1′,2′,5′,6′,7′,7a′-hexahydrospiro[indoline-3,3′-pyrrolizin]-2-one ( 8b ). Yellow solid, yield: 64%. m.p: 192°C. IR (KBr): 1712, 1656 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz): δ 1.65–1.72 (m, 4H), 1.78 (m, 2H), 1.96 (m, 2H), 2.01 (S, 6H), 2.48 (m, 2H), 3.81 (m, 2H), 4.04 (m, 2H), 4.85 (d, J = 11.10 Hz, 2H), 5.18 (m, 2H), 6.52–7.41 (m, 20H), 8.32 (s, 2H). ¹³C NMR (75 MHz); ppm 24.12, 27.45, 30.02, 36.91, 45.52, 54.57, 62.38, 71.17, 118.37, 125.51, 126.37, 128.23, 128.91, 130.15, 130.79, 132.24, 135.47, 137.76, 179.82, 201.31. MS (EI); m/z = 767.6 (M⁺). Anal. Calcd for: C₅₀H₄₆N₄O₄: C, 78.30; H, 6.05; N, 7.31; found; C, 78.37; H, 6.11; N, 7.27.

(2′R,3R)-2′-(2-Hydroxybenzoyl)-1′-(4-((2′S,3S)-2′-(2-hydroxybenzoyl)-2-oxo-1′,2′,5′,6′,7′,7a′-hexahydrospiro[indoline-3,3′-pyrrolizine]-1′-yl)phenyl)-1′,2′,5′,6′,7′,7a′-hexahydrospiro[indoline-3,3′-pyrrolizin]-2-one ( 8c ). Yellow solid, yield: 68%. m.p: 146°C. IR (KBr): 3052, 1739, 1619 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz): δ 1.67–1.78 (m, 4H), 1.78 (m, 2H), 1.86–1.92 (m, 2H), 2.22 (m, 2H), 2.53 (m, 2H), 2.95 (m, 2H), 3.82 (m, 2H), 4.49 (d, J = 11.10 Hz, 2H), 5.67 (m, 2H), 6.59–7.62 (m, 20H), 8.07 (s, 2H). 12.08 (s, 2H), ¹³C NMR (75 MHz); ppm 26.48, 29.44, 37.48, 49.97, 54.35, 67.72, 70.97, 118.38, 120.07, 121.37, 121.84, 122.58, 123.39, 125.17, 127.15, 128.81, 130.07, 131.18, 133.83, 136.62, 136.91, 178.82, 202.11. MS (EI); m/z = 771.4 (M⁺). Anal. Calcd for: C₄₈H₄₂N₄O₆: C, 74.79; H, 5.49; N, 7.27; found; C, 74.85; H, 5.41; N, 7.22.

2.3. General Procedure for Synthesis of Cycloadducts, 10a–c and 11a–c

To a solution of acenaphthenequinone 5/isatin 7 (2 eq), pipecolinic acid 9 (3 eq) in dry toluene (15 mL) bischalcones 3a–c (1eq) was added. The solution was refluxed until the completion of the reaction (6–8 h) as evidenced by TLC analysis. The solvent was removed in vacuo, and the crude product was subjected to column chromatography on silica gel (100–200 mesh) using petroleum ether/ethyl acetate (8 : 2) as eluent.

(1′R,2′R,8a′S)-2′-Benzoyl-1′-(4-((1S,1′S,2′S,8a′R)-2′-benzoyl-2-oxo-2′,5′,6′,7′,8′,8a′-hexahydro-1′H,2H-spiro[acenaphthylene-1,3′-indolizine]-1′-yl)phenyl)-2′,5′,6′,7′,8′,8a′-hexahydro-1′H,2H-spiro[acenaphthylene-1,3′-indolizin]-2-one ( 10a ). Yellow solid, yield: 72%. m.p: 138°C. IR (KBr): 1721, 1658 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz): δ 1.19–1.31 (m, 5H), 1.35–1.42 (m, 2H), 1.78 (m, 3H), 2.22 (m, 2H), 2.36 (m, 2H), 3.68 (m, 2H), 4.03 (m, 2H), 4.45 (d, J = 9.6 Hz, 2H), 4.77 (m, 2H), 6.96–8.27 (m, 26H). ¹³C NMR (75 MHz); ppm 23.74, 25.74, 30.66, 45.86, 52.00, 61.49, 66.07, 76.11, 120.50, 121.67, 122.08, 123.43, 124.56, 127.11, 127.39, 127.67, 128.50, 128.61, 128.77, 129.37, 131.68, 131.82, 132.02, 132.64, 132.69, 133.54, 136.85, 137.64, 138.33, 142.40, 143.81, 144.79, 198.00, 210.04. MS (EI); m/z = 837.9 (M⁺). Anal. Calcd for: C₅₈H₄₈N₂O₄: C, 83.23; H, 5.78; N, 3.35; found; C, 83.34; H, 5.67; N, 3.28.

(1′R,2′R,8a′S)-2′-(4-Methylbenzoyl)-1′-(4-((1S,1′S,2′S,8a′R)-2′-(4-methylbenzoyl)-2-oxo-2′,5′,6′,7′,8′,8a′-hexahydro-1′H,2H-spiro[acenaphthylene-1,3′-indolizine]-1′-yl)phenyl)-2′,5′,6′,7′,8′,8a′-hexahydro-1′H,2H-spiro[acenaphthylene-1,3′-indolizin]-2-one ( 10b ). Yellow solid, yield: 65%. m.p: 120°C. IR (KBr): 1739, 1657 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz): δ 1.25–1.51 (m, 5H), 1.73 (m, 3H), 1.85 (m, 2H), 1.97 (s, 6H), 2.25 (m, 2H), 2.42 (m, 2H), 3.67 (m, 2H), 4.12 (m, 2H), 4.43 (d, J = 9.3 Hz, 2H), 4.52 (m, 2H), 6.53–8.28 (m, 24H). ¹³C NMR (75 MHz); ppm 21.68, 23.75, 25.74, 29.67, 45.88, 52.11, 61.30, 66.07, 77.50, 120.47, 122.08, 123.48, 124.50, 126.53, 127.47, 128.12, 128.66, 129.32, 132.67, 134.49, 137.66, 142.85, 143.56, 197.62, 205.61. MS (EI); m/z = 865.6 (M⁺). Anal. Calcd for: C₆₀H₅₂N₂O₄: C, 83.30; H, 6.06; N, 3.24; found; C, 83.37; H, 6.11; N, 3.16.

(1′R,2′R,8a′S)-2′-(2-Hydroxybenzoyl)-1′-(4-((1S,1′S,2′S,8a′R)-2′-(2-hydroxybenzoyl)-2-oxo-2′,5′,6′,7′,8′,8a′-hexahydro-1′H,2H-spiro[acenaphthylene-1,3′-indolizine]-1′-yl)phenyl)-2′,5′,6′,7′,8′,8a′-hexahydro-1′H,2H-spiro[acenaphthylene-1,3′-indolizin]-2-one ( 10c ). Yellow solid, yield: 70%. m.p: 134°C. IR (KBr): 3021, 1729, 1662 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz): δ 1.25–1.47 (m, 5H), 1.70 (m, 2H), 1.79 (m, 3H), 2.20 (m, 2H), 2.34 (m, 2H), 3.65 (m, 2H), 3.99 (m, 2H), 4.43 (d, J = 9.0 Hz, 2H), 4.58 (m, 2H), 5.92–8.29 (m, 24H), 11.85 (s, 2H). ¹³C NMR (75 MHz); ppm 23.70, 29.36, 29.70, 46.00, 51.39, 60.63, 66.42, 77.25, 117.55, 118.85, 122.08, 124.62, 127.74, 128.58, 129.76, 131.01, 131.98, 132.66, 133.44, 135.35, 145.85, 193.32, 206.12. MS (EI); m/z = 869.4 (M⁺). Anal. Calcd for: C₅₈H₄₈N₂O₆: C, 80.16; H, 5.57; N, 3.22; found; C, 80.27; H, 5.49; N, 3.19.

(1′R,2′R,3R,8a′S)-2′-Benzoyl-1′-(4-((1′S,2′S,3S,8a′R)-2′-benzoyl-2-oxo-2′,5′,6′,7′,8′,8a′-hexahydro-1′H-spiro[indoline-3,3′-indolizine]-1′-yl)phenyl)-2′,5′,6′,7′,8′,8a′-hexahydro-1′H-spiro[indoline-3,3′-indolizin]-2-one ( 11a ). Yellow solid, yield: 65%. m.p: 198°C. IR (KBr): 1718, 1639 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz): δ 1.18–1.36 (m, 4H), 1.42 (m, 3H), 1.81 (m, 4H), 2.26 (m, 2H), 2.34 (m, 2H), 3.37 (m, 2H), 3.75 (m, 2H), 4.33 (d, J = 9.9 Hz, 2H), 4.57 (m, 2H), 6.75–7.86 (m, 22H), 8.42 (s, 2H). ¹³C NMR (75 MHz); ppm 24.48, 26.38, 30.07, 45.48, 51.97, 59.37, 65.78, 71.37, 120.39, 121.44, 124.39, 125.78, 127.01, 127.67, 128.18, 128.97, 129.58, 132.78, 133.86, 137.15, 139.39, 141.15, 178.93, 197.39. MS (EI); m/z = 767.4 (M⁺). Anal. Calcd for: C₅₀H₄₆N₄O₄: C, 78.30; H, 6.05; N, 7.31; found; C, 78.43; H, 6.01; N, 7.26.

(1′R,2′R,3R,8a′S)-2′-(4-Methylbenzoyl)-1′-(4-((1′S,2′S,3S,8a′R)-2′-(4-methylbenzoyl)-2-oxo-2′,5′,6′,7′,8′,8a′-hexahydro-1′H-spiro[indoline-3,3′-indolizine]-1′-yl)phenyl)-2′,5′,6′,7′,8′,8a′-hexahydro-1′H-spiro[indoline-3,3′-indolizin]-2-one ( 11b ). Yellow solid, yield: 67%. m.p: 194°C. IR (KBr): 1721, 1646 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz): δ 1.18–1.38 (m, 3H), 1.51 (m, 3H), 1.88 (m, 2H), 1.92 (s, 6H), 2.09 (m, 2H), 2.32 (m, 2H), 3.22 (m, 2H), 3.61 (m, 2H), 4.09 (m, 2H), 4.40 (d, J = 9.9 Hz, 2H), 4.59 (m, 2H), 6.39–7.85 (m, 20H), 8.30 (s, 2H). ¹³C NMR (75 MHz); ppm 22.63, 25.90, 29.47, 30.91, 44.61, 50.44, 59.69, 64.33, 71.49, 107.77, 121.74, 123.36, 125.76, 126.70, 127.11, 127.11, 127.65, 128.34, 129.91, 133.96, 137.65, 139.65, 142.11, 179.86, 196.12. MS (EI); m/z = 795.5 (M⁺). Anal. Calcd for: C₅₂H₅₀N₄O₄: C, 78.56; H, 6.34; N, 7.05; found; C, 78.62; H, 6.28; N, 7.13.

(1′R,2′R,3R,8a′S)-2′-(2-Hydroxybenzoyl)-1′-(4-((1′S,2′S,3S,8a′R)-2′-(2-hydroxybenzoyl)-2-oxo-2′,5′,6′,7′,8′,8a′-hexahydro-1′H-spiro[indoline-3,3′-indolizine]-1′-yl)phenyl)-2′,5′,6′,7′,8′,8a′-hexahydro-1′H-spiro[indoline-3,3′-indolizin]-2-one ( 11c ). Yellow solid, yield: 66%. m.p: 186°C. IR (KBr): 3037, 1718, 1651 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz): δ 1.27–1.42 (m, 4H), 1.56 (m, 3H), 1.98 (m, 3H), 2.39 (m, 2H), 2.48 (m, 2H), 3.57 (m, 2H), 3.67 (m, 2H), 4.45 (d, J = 9.6 Hz, 2H), 4.76 (m, 2H), 6.57–7.89 (m, 20H), 8.39 (s, 2H), 11.91 (s, 2H). ¹³C NMR (75 MHz); ppm 23.60, 25.50, 30.52, 45.70, 51.36, 60.26, 65.19, 73.04, 118.62, 119.20, 119.79, 120.19, 123.13, 126.17, 127.30, 128.49, 129.24, 133.48, 136.42, 143.55, 144.82, 180.43, 202.91. MS (EI); m/z = 799.6 (M⁺). Anal. Calcd for: C₅₀H₄₆N₄O₆: C, 75.17; H, 5.80; N, 7.01; found; C, 75.24; H, 5.78; N, 7.08.

3. Materials and Methods for Antimicrobial Studies

We have carried out bioactivity studies for the synthesized compounds against six microorganisms, Escherichia coli, Bacillus subtilis, Staphylococcus aureus, Salmonella typhi, Proteus vulgaris, and Proteus mirabilis which were obtained from the Microbial Metabolite Lab Culture collection, University of Madras, Chennai.

The agar diffusion method was used for the determination of antibacterial activity of dispiropyrrolizidines against microorganism listed above. About 9 mL of nutrient agar media were poured into petri plates (9 cm in diameter) and inoculated with respective test organism. Wells are made with cork borer on the solid agar and loaded with 20–60 µg/mL of the test compound with tetracycline as control. Petri dishes were incubated at 37°C for 24 h, and the average diameter of the inhibition zone surrounding the wells was measured after specified incubation period.

4. Results and Discussion

4.1. Chemistry

The bischalcones used as dipolarophiles for the present study were prepared according to the Claisen-Schmidt reaction, by reacting various substituted acetophenones 1a–c with terephthalaldehyde 2 and NaOH (60%) as a base to give pale yellow products 3a–c (80–86%) (Scheme 1).

Scheme 1

The products 3a–c were assigned the (E)-configuration based on the chemical shift value of olefinic protons in accordance with the literature data [18–22].

We have explored the reactivity of bischalcone derivatives as efficient dipolarophiles for the synthesis of a rare class of dispiroheterocycles. The azomethine ylide generated in situ through decarboxylative condensation reaction from L-proline 4 and acenaphthenequinone 5/isatin 7 reacted with bischalcone derivatives 3a–c as dipolarophiles in refluxing toluene under the Dean-Stark reaction condition to afford a series of novel dispiro pyrrolizidines 6a–c and 8a–c (Scheme 2).

Scheme 2

The structures of these products were also confirmed by ¹H NMR, ¹³C NMR, DEPT, COSY, NOESY, and mass spectral analysis. The ¹H NMR spectrum of 6b showed a multiplet at δ 5.22 for benzylic H₂ proton. The benzoyl proton H₁ resonated as a doublet at δ 4.91 (J = 11.10 Hz), and H₃ proton appeared as a multiplet at δ 4.19–4.26. The stereochemistry of the cycloadduct 6b was deduced on the basis of 2D NOESY experiments. The strong NOESY between H₂ and H₃ shows cis stereochemistry, and when there is no NOESY between H₁ and H₂ of 6b shows trans stereochemistry. The ¹³C NMR spectrum of 6b showed a signal at 76.44 ppm for the spiro carbon. The peaks at 52.19 ppm and 63.18 ppm correspond to the benzylic –CH– carbon and N–CH– carbon of 10b and were confirmed by DEPT 135 spectrum. Acenaphthenequinone carbonyl carbon appeared at 205.33 ppm, and the benzoyl carbon resonated at 196.86 ppm. Moreover, the cycloadduct 6b exhibited a peak at m/z = 837.3 (M⁺) in the mass spectrum.

With a view to explore the potential of the cycloaddition reaction of 1,3-dipole for the synthesis of spiroheterocycles, we have carried out the reaction of the azomethine ylide generated from pipecolinic acid 9 and acenaphthenequinone 5/isatin 7 with bischalcones as dipolarophiles to give dispiro pyrrolizidines 10a–c and 11a–c (Scheme 3).

Scheme 3

The IR spectrum of the cycloadduct 11c showed peaks at 1651 and 1718 cm⁻¹ which correspond to the amide and benzoyl carbonyl groups, respectively. The ¹H NMR spectrum of 11c showed a multiplet at δ 4.76 for benzylic H₂ proton. The benzoyl proton H₁ resonated as a doublet at δ 4.45 (J = 9.6 Hz), and H₃ proton appeared as a multiplet at δ 3.95–4.01. The stereochemistry of the cycloadduct 11c was deduced on the basis of 2D NOESY experiments. The strong NOESY between H₂ and H₃ shows cis stereochemistry, and when there is no NOESY between H₁ and H₂ of 11c shows trans stereochemistry. The –NH proton of the oxindole moiety appeared as a singlet at δ 8.39, and the –OH peak appeared as a singlet at δ 11.91. The ¹³C NMR spectrum of 11c showed a signal at 73.04 ppm for the spiro carbon. The N–CH carbon of 11c resonated at 60.26 ppm and was confirmed by DEPT 135 spectrum. The peaks at 202.91 and 180.43 ppm correspond to the benzoyl and amide carbonyl groups. Moreover, the cycloadduct 11c exhibited a peak at m/z = 799.6 (M⁺) in the mass spectrum.

5. Biology

5.1. Antimicrobial Activity of Dispiropyrrolizidines (Agar Diffusion Assay)

The agar diffusion method [23] was used for the determination of antibacterial activity of dispiropyrrolizidines against microorganism listed above. The results of the antimicrobial screening of the twelve compounds have been listed in Tables 1, 2, 3, 4, 5, and 6.

Table 1: Effect of dispiro pyrrolizidines on the growth of human pathogen Proteus mirabilis.

Organism
Compound
Concentration of compound (µg/mL)

20
40
60

Zone of inhibition (mm)

Proteus mirabilis
6a
—
14
19

6b
—
13
18

6c
—
17
21

8a
—
10
18

8b
—
15
23

8c
11
19
22

10a
—
10
15

10b
—
—
9

10c
—
18
22

11a
—
11
18

11b
—
14
19

11c
12
18
23

Tetracycline
16
20
24

Table 2: Effect of dispiro pyrrolizidines on the growth of human pathogen Proteus vulgaris.

Organism
Compound
Concentration of compound (µg/mL)

20
40
60

Zone of inhibition (mm)

Proteus vulgaris
6a
—
12
18

6b
—
13
19

6c
—
15
21

8a
—
14
20

8b
—
13
21

8c
10
18
23

10a
—
9
13

10b
—
—
7

10c
—
19
23

11a
—
10
17

11b
9
14
19

11c
12
19
23

Tetracycline
18
22
25

Table 3: Effect of dispiro pyrrolizidines on the growth of human pathogen Salmonella typhi.

Organism
Compound
Concentration of compound (µg/mL)

20
40
60

Zone of inhibition (mm)

Salmonella typhi
6a
—
11
17

6b
—
9
11

6c
—
15
21

8a
—
13
18

8b
—
12
19

8c
11
19
25

10a
—
9
12

10b
—
8
12

10c
—
16
21

11a
—
11
18

11b
—
14
19

11c
12
20
26

Tetracycline
17
21
26

Table 4: Effect of dispiro pyrrolizidines on the growth of human pathogen Staphylococcus aureus.

Organism
Compound
Concentration of compound (µg/mL)

20
40
60

Zone of inhibition (mm)

Staphylococcus aureus
6a
—
15
19

6b
—
9
11

6c
—
17
21

8a
—
10
18

8b
—
15
22

8c
9
17
24

10a
—
10
15

10b
—
—
9

10c
—
18
23

11a
—
11
18

11b
—
14
19

11c
10
19
23

Tetracycline
18
21
24

Table 5: Effect of dispiro pyrrolizidines on the growth of human pathogen Bacillus subtilis.

Organism
Compound
Concentration of compound (µg/mL)

20
40
60

Zone of inhibition (mm)

Bacillus subtilis
6a
—
12
18

6b
—
9
14

6c
—
15
21

8a
—
10
18

8b
—
15
22

8c
9
17
21

10a
—
8
14

10b
—
—
13

10c
—
18
23

11a
—
11
18

11b
—
14
19

11c
9
19
22

Tetracycline
14
19
21

Table 6: Effect of dispiro pyrrolizidines on the growth of human pathogen Escherichia coli.

Organism
Compound
Concentration of compound (µg/mL)

20
40
60

Zone of inhibition (mm)

Escherichia coli
6a
—
11
18

6b
—
7
15

6c
—
15
21

8a
—
15
22

8b
—
10
18

8c
9
18
22

10a
—
10
15

10b
—
—
9

10c
—
19
23

11a
—
14
19

11b
—
11
17

11c
11
19
23

Tetracycline
16
20
23

It was observed that the synthetic compounds 6c, 8b, 8c, 10c, and 11c exhibited good antimicrobial activity and inhibition zones against the pathogen Proteus mirabilis while 6a, 6b, 8a, 10a, 11a, and 11b showed moderate activity. All other derivatives did not show appreciable activity at low concentration. For P. vulgaris the compounds 11c, 10c, and 8c showed very good antibacterial activity which is comparable to that of reference compound tetracycline, and 6a, 6b, 6c, 8a, 8b, 11a, and 11b showed moderate inhibitory activity against this pathogen. The compounds 11c and 8c showed very good antimicrobial activity against the pathogen Salmonella typhi while 6c, 10c, 8b, 8a, 6a, 11b, and 11a showed moderate activity. The compounds 8c, 11c, 10c, and 8b exhibited good antibacterial activity, while 6c, 6a, 8a, 11a, and 11b showed moderate activity against the pathogen Staphylococcus aureus. All other compounds showed low activity. The inhibitory activity of the compounds 10c, 11c, 8b, 8c, and 6c against the bacteria Bacillus subtilis was observed to be good while 6a, 8a, 11a, and 11b showed moderate activity against this pathogen. The compounds 11c, 10c, 8c, 6c, and 8a showed good antimicrobial activity against the pathogen Escherichia coli while 6a, 8b, 11a, and 11b showed moderate activity, and all other compounds showed low activity.

Some of the oxindole derived compounds and acenaphthenequinone derived compounds showed good activity against all the pathogens in low concentration, which is comparable to the reference control. It was observed that all the antibacterial activities of the presently studied compounds are dose dependent. The oxindole derived compounds 11c and 8c showed good activity against all the test pathogens. The activity was very much comparable to the reference drug. The acenaphthenequinone derived compounds 6c and 10c showed good activity against all the test pathogens. Hydroxy substituted dispiropyrrolizidines 11c, 10c, 8c, and 6c showed very good antibacterial activity against all the pathogens studied. Further clinical studies are required to validate the compounds of the present study as antimicrobial agents. The results are summarized in Tables 1, 2, 3, 4, 5, and 6.

6. Conclusion

In conclusion, we have achieved the synthesis of a variety of novel dispiro pyrrolizidines through 1,3-dipolar cycloaddition reaction and evaluated their structure by using different spectroscopic techniques. Most of the synthesized compounds showed good antimicrobial activity against all the selected human pathogens. In particular, cycloadducts, 11c, 8c, 10c, and 6c, exhibited the best antibacterial activity against all the bacterial pathogens.

Acknowledgments

N. Sirisha thanks CSIR New Delhi for the award of SRF and DST for JRF. R. Raghunathan thanks DST-FIST for NMR facility. The authors wish to thank Professors N. Raaman and R. Jegadeesh for the biological study.

References

A. Padwa, 1, 3-Dipolar Cycloaddition Chemistry, vol. 1-2, John Wiley & Sons, New York, NY, USA, 1984.

V. C. Pham and J. L. Charlton, “Methyl (S)-lactate as a chiral auxiliary in the asymmetric synthesis of Bao Gong Teng A,” Journal of Organic Chemistry, vol. 60, no. 24, pp. 8051–8055, 1995.

C. W. G. Fiswick, R. J. Foster, and R. E. Carr, “A short dipolar cycloaddition approach to γ-lactam alkaloids from cynometra hankei,” Tetrahedron Letters, vol. 37, no. 22, pp. 3915–3918, 1996.

J. Obniska, A. Zeic, and A. Zagorska, “Synthesis and anticonvulsant properties of new 1-phenyl and 1-phenylamino-3-phenylpyrrolidine-2,5-dione derivatives,” Acta Poloniae Pharmaceutica, vol. 59, no. 3, pp. 209–213, 2002.

A. Padwa, B. M. Trost, and I. Fleming, Eds., Comprehensive Organic Synthesis, vol. 4, Pergamon, Oxford, UK, 1991.

G. Periyasami, R. Raghunathan, G. Surendiran, and N. Mathivanan, “Synthesis of novel spiropyrrolizidines as potent antimicrobial agents for human and plant pathogens,” Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 7, pp. 2342–2345, 2008.

R. S. Kumar, S. M. Rajesh, S. Perumal, D. Banerjee, P. Yogeeswari, and D. Sriram, “Novel three-component domino reactions of ketones, isatin and amino acids: synthesis and discovery of antimycobacterial activity of highly functionalised novel dispiropyrrolidines,” European Journal of Medicinal Chemistry, vol. 45, no. 1, pp. 411–422, 2010.

J. Mojzisa, L. Varinskaa, G. Mojzisovab, I. Kostovac, and L. Mirossaya, “Antiangiogenic effects of flavonoids and chalcones,” Pharmacological Research, vol. 57, no. 4, pp. 259–265, 2008.

D. N. Dhar, The Chemistry of Chalcones and Related Compounds, John Wiley & Sons, New York, NY, USA, 1981.

Z. Nowakowska, B. K. Dzia, and G. Schroede, “Synthesis, physicochemical properties and antimicrobial evaluation of new (E)-chalcones,” European Journal of Medicinal Chemistry, vol. 43, no. 4, pp. 707–713, 2008.

F. Chimenti, R. Fioravanti, A. Bolasco et al., “Chalcones: a valid scaffold for monoamine oxidases inhibitors,” Journal of Medicinal Chemistry, vol. 52, no. 9, pp. 2818–2824, 2009.

R.-I. Tsukiyama, H. Katsura, N. Tokuriki, and M. Kobayashi, “Antibacterial activity of licochalcone A against spore-forming bacteria,” Antimicrobial Agents and Chemotherapy, vol. 46, no. 5, pp. 1226–1230, 2002.

K. L. Lahtchev, D. I. Batovska, S. P. Parushev, V. M. Ubiyvovk, and A. A. Sibirny, “Antifungal activity of chalcones: a mechanistic study using various yeast strains,” European Journal of Medicinal Chemistry, vol. 43, no. 10, pp. 2220–2228, 2008.

S. J. Won, C. T. Liu, L. T. Tsao et al., “Synthetic chalcones as potential anti-inflammatory and cancer chemopreventive agents,” European Journal of Medicinal Chemistry, vol. 40, no. 1, pp. 103–112, 2005.

B. P. Bandgar, S. S. Gawande, R. G. Bodade, J. V. Totre, and C. N. Khobragade, “Synthesis and biological evaluation of simple methoxylated chalcones as anticancer, anti-inflammatory and antioxidant agents,” Bioorganic and Medicinal Chemistry, vol. 18, no. 3, pp. 1364–1370, 2010.

V. J. Ram, A. S. Saxena, S. Srivastava, and S. Chandra, “Oxygenated chalcones and bischalcones as potential antimalarial agents,” Bioorganic and Medicinal Chemistry Letters, vol. 10, no. 19, pp. 2159–2161, 2000.

J. Naga Siva Rao and R. Raghunathan, “An expedient diastereoselective synthesis of pyrrolidinyl spirooxindoles fused to sugar lactone via [3 + 2] cycloaddition of azomethine ylides,” Tetrahedron Letters, vol. 53, no. 7, pp. 854–858, 2012.

A. R. Bhat, F. Athar, and A. Azam, “Bis-pyrazolines: synthesis, characterization and antiamoebic activity as inhibitors of growth of Entamoeba histolytica,” European Journal of Medicinal Chemistry, vol. 44, no. 1, pp. 426–431, 2009.

N. Li, S.-L. Lai, W. Liu et al., “Synthesis and properties of n-type triphenylpyridine derivatives and applications in deep-blue organic light-emitting devices as electron- transporting layer,” Journal of Materials Chemistry, vol. 21, no. 34, pp. 12977–12985, 2011.

J.-F. Zhou, J.-F. Zhou, Z.-C. Zou, and J.-C. Feng, “A facile synthesis of 1,4-bis-(3-Aryl-3-oxo-1-propenyl)benzenes under microwave irradiation,” Synthetic Communications, vol. 32, no. 21, pp. 3389–3392, 2002.

D. C. G. A. Pinto, A. M. S. Silva, J. A. S. Cavaleiro, and J. Elguero, “New bis(chalcones) and their transformation into bis(pyrazoline) and bis(pyrazole) derivatives,” European Journal of Organic Chemistry, vol. 38, no. 4, pp. 747–755, 2003.

G. Wurm and H. Loth, “Synthesis and properties of symmetrical bis(chromonyl-2)-benzol derivatives,” Archiv der Pharmazie und Berichte der Deutschen Pharmazeutischen Gesellschaft, vol. 303, no. 5, pp. 428–434, 1970.

M. W. Jenny, “Methods for testing the antimicrobial activity of extracts,” in Modern Phytomedicine, Turning Medicinal Plants into Drugs, I. Ahmad, F. Aqil, and M. Owais, Eds., p. 157, WILEY-VCH, Weinheim, Germany, 2006.